Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...
Mackie Research Capital raised its price target for Aleafia Health (TSX:AH) to $1.50 (Canadian) from $1, citing an exclusive agreement with Unifor, Canada’s largest private sector union, to support medical cannabis for...
Mackie Research Capital initiated coverage of Newtopia (TSXV:NEWU) with a “speculative buy” rating and price target of $1.10 (Canadian). The stock closed at 62 cents on Jan. 11. Newtopia is a fast-growing healthcare...
Mackie Research Capital raised its price target for Medexus Pharmaceuticals (TSXV:MDP; OTCQX:MEDXF) to $9 (Canadian) from $6.30, citing positive momentum in sales of the company’s key drugs. The stock closed at $6.11 on...
Mackie Research Capital initiated coverage of CB2 Insights (CSE:CBII) with a “speculative buy” rating and price target of $1.10. The stock closed at 59 cents on Oct. 23. CB2 Insights is a health care services and...